Cancer Cell Cytotoxicity of Marinopyrroles, Pyrrolomycins, and Their Derivatives
Marine Drugs · 16.10.2025 · 23 (10) · 403
DOI: 10.3390/md23100403 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Marine Drugs, online erschienen am 16.10.2025. Verfasst von Jeffrey M Zimmerly und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, University of Nebraska at Omaha, Omaha, NE 68182, USA. Hauptthemen laut MEDLINE: Pyrroles, Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NIH HHS, Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health Grant.
Abstract (Originalsprache)
Marine-derived secondary metabolites have emerged as a rich potential source of anticancer agents, with marinopyrroles and pyrrolomycins representing structurally distinct halogenated pyrroles of interest. Initially characterized for their potent antibacterial properties, these compounds were later shown to exert cytotoxic activity across diverse hematologic and solid malignancies, frequently correlating with Mcl-1 dependence. Marinopyrrole A, a marine-derived natural product, exemplified this potential by inducing proteasomal degradation of Mcl-1, thereby sensitizing resistant cancer cells to Bcl-2 inhibitors and TRAIL-based therapies. In parallel, pyrrolomycins, particularly pyrrolomycin C and members of the F-series, demonstrated potent activity with submicromolar IC50 concentrations across multiple cancer cell lines, and also perturbed cytoskeletal and membrane integrity. Together, these halogenated pyrroles illustrate multifaceted cancer cell cytotoxicity profiles but face translational barriers, including mechanistic ambiguity, poor solubility, and off-target toxicities. To address these limitations, extensive medicinal chemistry efforts have yielded synthetic derivatives with improved potency, selectivity, and drug-like properties, with notable examples such as MP1 and KS18 showing enhanced efficacy in MYC-driven neuroblastoma, medulloblastoma, and drug-resistant multiple myeloma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biology, University of Nebraska at Omaha, Omaha, NE 68182, USA.
- College of Medicine, University of Nebraska Medical Center, Omaha, NE 68198, USA.
- Department of Microbiology and Molecular Biology, Brigham Young University, Provo, UT 84604, USA.
ORCID-Profile: Clare F Euteneuer, Brianna N Davis, Angelique Vargas, Paul H Davis
Förderung
- NIGMS NIH HHS
- NIH HHS
- Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health Grant
- The University of Nebraska GRACA, FUSE, and NU Collaboration Initiative
Zitieren
APA
Zimmerly, J. M., Armstrong, N. A., Euteneuer, C. F., Davis, B. N., Griffis-Anchala, M. B., Vargas, A., & Davis, P. H. (2025). Cancer Cell Cytotoxicity of Marinopyrroles, Pyrrolomycins, and Their Derivatives. Marine Drugs, 23(10), 403. https://doi.org/10.3390/md23100403
Vancouver
Zimmerly JM, Armstrong NA, Euteneuer CF, Davis BN, Griffis-Anchala MB, Vargas A, et al. Cancer Cell Cytotoxicity of Marinopyrroles, Pyrrolomycins, and Their Derivatives. Marine Drugs. 2025;23(10):403. doi:10.3390/md23100403
BibTeX
@article{Zimmerly2025,
author = {Zimmerly, Jeffrey M and Armstrong, Nicholas A and Euteneuer, Clare F and Davis, Brianna N and Griffis-Anchala, M Beth and Vargas, Angelique and Davis, Paul H},
title = {Cancer Cell Cytotoxicity of Marinopyrroles, Pyrrolomycins, and Their Derivatives},
journal = {Marine Drugs},
year = {2025},
volume = {23},
number = {10},
pages = {403},
doi = {10.3390/md23100403}
}
EUVIMED